Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of B-hCD23 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0237-LGZ)

Introduction

Introduction of model mice<br />Strain Name: C57BL/6N-Fcer2atm1(FCER2)/Bcgen <br />Common Name: B-hCD23 mice<br />Background: C57BL/6<br />Aliases: CD23(BLAST-2, CD23, CD23A, CLEC4J, FCE2, FCErII, IGEBF)




Principle

Target humanized mice are animal models in which drug targets or disease-related human proteins are knocked in to destroy mouse homologous proteins. The mouse model has a healthy immune system and can be used to evaluate the efficacy of immunotherapy. At the same time, human protein was used to replace mouse homologous protein, which overcame the problem that some antibodies could not be cross-recognized between human and mouse. Human or humanized antibody drugs could be used for efficacy evaluation, which solved the difficulty of only using alternative anti-mouse antibodies for efficacy evaluation in the past, and greatly reduced the cost of research and development while improving the conversion rate of drug development. In addition, compared with the immune reconstruction model of immunodeficient mice and human, the results are more cost-effective and stable.
We have developed a series of single target/double target or multi-target humanized mouse models according to the current market demand for new drug research and development, and developed corresponding humanized tumor cell lines according to the possible mechanism of drug action, in order to provide a more complete and effective disease model for pharmacodynamic evaluation.

Applications

In vivo pharmacodynamic analysis was performed by Immune Checkpoint Humanized Mice.

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder